Elicera Therapeutics
Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue
On 20 February 2024 the extraordinary general meeting of the Company resolved on a rights issue of units of approximately SEK 64 million (the “Rights Issue”). The subscription period in the Rights Issue started on 23 February 2024 and ends 8 March 2024. Elicera has received additional subscription commitments from the following members of the board and management who intend to subscribe in the Rights Issue:
| Shareholder | Role in the Company | Initial commitment, SEK | Increased commitment, SEK |
| Jamal El-Mosleh | CEO | 250,000 | 100,000 |
| Di Yu | Head of Translational Research and co-fonder | 100,000 | 100,000 |
| Jan Zetterberg | Board member | 0 | 230,000 |
| Total | 350,000 | 430,000 |
Through these subscription commitments, the board and management demonstrate their continued confidence in Elicera’s future prospects. Overall the subscription commitments from the board and management amount to approximately 1 million SEK.
| Datum | 2024-03-04, kl 14:00 |
| Källa | Cision |
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.